Navigation Links
Mentice AB Announces the Appointment of Lars Lonn as Clinical Director for Mentice
Date:3/28/2008

GOTHENBURG, Sweden, March 28 /PRNewswire/ -- Mentice AB, a leading supplier of virtual reality based training applications within the field of medicine has recently appointed Lars Lonn as Clinical Director for Mentice.

Professor Lonn, an Interventional Radiologist, is also a leading European professor within the field of Endovascular Surgery and a faculty member of Rigshospital Health Sciences in Copenhagen, Denmark.

Professor Lonn recently completed a study with Max Berry, MD, Mikael Hellstrom, MD, Jan Gothlin, MD, and Richard Reznick, MD, MEd, FRCSC, which was featured in the Journal of Vascular Interventional Radiology entitled, "Endovascular Training with Animals versus Virtual Reality Systems: An Economic Analysis."

Goran Malmberg, CEO and President of Mentice said, "This is a monumental step forward for us. Professor Lonn will have a vital role with Mentice verifying the direction of our product development, while increasing the awareness and need for training solutions in healthcare. In the long run, we feel that Clinical Directors will play a vital role in driving medical training through the use of medical simulation."

About Mentice:

Mentice is a leader in medical simulation with approximately 600 installations worldwide, 100 validation studies and more than 30 issued and pending patents. Mentice's Family of Procedicus (TM) simulators focus on the area of minimally invasive surgery within the fields of endovascular intervention, core skills training, laparoscopy and arthroscopy training.

Website info: http://www.mentice.com

For more information contact: Goran Malmberg at +46 31 33 99 401 (Gothenburg office) or email, goran.malmberg@mentice.com.

Release #32808


'/>"/>
SOURCE Mentice Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility ... Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski will ... Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE mark ...
(Date:12/2/2016)... -- The Multiple Myeloma Research Foundation (MMRF) today announced that ... —the largest and most comprehensive study driving new genomic ... presented at the 58 th American Society of ... San Diego from December 3-6. The new ... as identify pathways and targets for new drug development. ...
(Date:12/2/2016)... 2016 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced the appointment of Earl Warren ... and private healthcare investor, to its Board of Directors. ... clinical and strategic experience at the highest level," said ... "As one of the world,s leading orthopedic surgeons, Dr. ...
(Date:12/2/2016)... Diego, CA (PRWEB) , ... December 01, 2016 , ... ... data from its Phase I/II clinical trials for AC0010 at the World Conference on ... forward to providing an update on the phase I/II clinical trials for AC0010 in ...
Breaking Biology Technology:
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
Breaking Biology News(10 mins):